We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer’s Hypertension Candidate Aces FDA Review, But Lower Doses Urged
Bayer’s Hypertension Candidate Aces FDA Review, But Lower Doses Urged
August 2, 2013
FDA briefing documents issued ahead of an advisory panel meeting to evaluate Bayer’s hypertension candidate Adempas give the drug a glowing review but also urge lower doses.